BioSpace News Archive

Aptorum Group Limited announced that its subsidiary company, Aptorum Innovations Holding Limited, has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.

Elevation Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, highlighted its 2021 corporate achievements and outlined its expected milestones for 2022.

Viking Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at the virtual H.C. Wainwright BioConnect Conference, which began at 7:00 a.m. EST on Monday, January 10, 2022.

Unicycive Therapeutics, Inc. announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

REGENXBIO Inc. announced the initiation of ASCENTTM, the second of two Phase III pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration.

Series E Financing led by EW Healthcare Partners with Robert S. White to Join Board.

Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2021 Crysvita® revenue in Ultragenyx territories and Dojolvi® global revenue, cash and investments at year end 2021, and provided 2022 revenue guidance for Crysvita in Ultragenyx territories and Dojolvi globally.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, announced today the initiation and first dosing in the Bioequivalence (BE) trial of the novel Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST.